2025 Multiple Myeloma – Integrating innovation from bench to clinic

Eventi 2025

2025 Multiple Myeloma – Integrating innovation from bench to clinic

Dates: 3/4 novembre 2025

Location: Genova, Italy

Over the recent years significant progress has been achieved in Multiple Myeloma biology resulting in novel therapeutic strategies as well as changes in the whole treatment paradigm. This international meeting aims to update the state of the art in Multiple Myeloma focusing on the latest biological and clinical advances. A number of internationally recognized speakers are expected to deliver updates lectures on cutting edge topics. These will include genetic and epigenetic features of biology, molecular and biological mechanisms of disease progression, new prognostic factors and novel approaches to evaluate the response to therapy, new therapeutic molecules and combinations targeting tumor cells and/or their microenvironment. Novel immunotherapy strategies will also be the object of intensive scrutiny.
We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by Multiple Myeloma may now be faced with more rational and effective achievements.

Prof. Roberto Massimo Lemoli, Meeting President

Additional information

Date

Monday, November 3, 2025
Tuesday, November 4, 2025

Location

STARHOTELS PRESIDENT

Corte dei Lambruschini, 4
16129 Genova GE

Meeting President

Prof. LEMOLI Roberto Massimo

Scientific Committee

CEA Michele (Chair)
CAGNETTA Antonia, CATINI Maria Elisabetta, GALLO Marco, GARIBOTTO Matteo, LASERRA Anna Elisa, OLIVIERI Marco

Faculty

ANGELUCCI Emanuele IRCCS Polyclinic S. Martino, Hematology and Cellular Therapies
Operational Unit – Genoa, Italy

BELLONE Matteo Maria IRCCS San Raffaele Hospital, Immunology Rheumatology Allergology
and Rare Diseases – Milan, Italy

BOLLI Niccolò University Milan, Hematology – Milan, Italy

BRINGHEN Sara AOU Città della Salute e della Scienza, Oncology – Turin, Italy

BRUNO Benedetto University Turin, AOU Città della Salute e della Scienza, Hematology –
Turin, Italy

CAGNETTA Antonia University Genoa, IRCCS Polyclinic S. Martino, Hematology Clinic –
Genoa, Italy

CAVO Michele University Bologna, Hematology – Bologna, Italy

CEA Michele University Genoa, IRCCS Polyclinic S. Martino, Hematology Clinic – Genoa, Italy

CHESI Marta Mayo Clinic – Dep. of Medicine, Scottsadale AZ, USA

D’AGOSTINO Mattia University Turin, AOU Città della Salute e della Scienza, Molecular Biotechnology and Health Science, Hematology – Turin, Italy

DA VIA’ Matteo Claudio IRCCS Ca’Granda Maggiore Hospital Polyclinic, Hematology – Milan, Italy

EINSELE Hermann Julius Maximilians University Würzburg, Internal Medicine II – Würzburg, Germany

GAY Francesca Maria University Turin, Molecular Biotechnology Health Science,Hematology,
Turin, Italy

GIULIANI Nicola University Parma, Hematology – Parma, Italy

GOBBI Marco University Genoa, Emeritus professor – Genoa, Italy

GULLA’ Annamaria Cancer Institute IRCCS, Lab. of Translational Hematology and Immunology – Candiolo TO, Italy

KORST Charlotte Amsterdam University, Dept Hematology – Amsterdam, The Netherlands

LEMOLI Roberto Massimo University Genoa, IRCCS Polyclinic S. Martino, Hematology Clinic – Genoa, Italy

MALAVASI Fabio University Turin, Emeritus professor – Turin, Italy

MATEOS MANTECA María Victoria Salamanca University, Biomedical Research Institute,Hematology Service – Salamanca, Spain

MORELLI Eugenio Cancer Institute IRCCS, Lab.Translational Research – Candiolo TO, Italy

RASCHE Leo Würzburg University, Dept. Internal Medicine – Würzburg, Germany

ROCCARO Aldo Maria ASST Spedali Civili, Clinical Trial Center, Translational Research and
Phase I Unit – Brescia, Italy

TACCHETTI Paola University Bologna, Polyclinic Sant’ Orsola, Institute Hematology “Seràgnoli» – Bologna, Italy

TERRAGNA Carolina IRCCS AOU Bologna, Polyclinic Sant’ Orsola, Lab. Molecular Biology – Bologna, Italy

ZAMAGNI Elena University Bologna, Polyclinic Sant’ Orsola, Institute Hematology “Seràgnoli» – Bologna, Italy

Programme

Monday, November 3, 2025

08:30 Registration

OPENING SESSION

09:00 Welcome address R.M. Lemoli, P. Ruggeri, A. Uccelli

09:30 Lecture – Cellular Therapies for Multiple Myeloma: Engineering Hope H. Einsele – Introducing R. M. Lemoli

BIOLOGY OF MULTIPLE MYELOMA: GENOMIC, EPIGENOMIC AND PROTEOMIC INSIGHTS

Chairpersons: N. Bolli, A. Roccaro

10:15 The supportive role of the endothelial niche in myeloma biology A. Roccaro
10:40 CD38, NAD+ Metabolism and Resistance Mechanisms F. Malavasi
11:05 Genomic complexity during disease progression from smouldering to multiple myeloma M.C. Da Vià
11:30 Unique molecular assay (UMA): a next generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma C. Terragna
11:55 Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmentalchanges N. Bolli
12:20 From targeted to cellular therapy: an unexpected role for RNA? E. Morelli

12:55 Lunch

IMMUNOMETABOLISM, MICROENVIROMENT AND IMMUNOTHERAPIES

Chairpersons: M. Cea, N. Giuliani

14:00 Unraveling the biological underpinning of tumor immune escape A. Gullà
14:25 New insights on myeloma bone disease pathogenesis N. Giuliani
14:50 The nutrition-microbiota immunity axis in multiple myeloma M.M. Bellone
15:15 Targeting metabolic pathways M. Cea

15:40 Coffee Break

PRECISION MEDICINE APPROACH AND REAL-WORLD DATA

Chairpersons: B. Bruno, M. Gobbi

16:00 Current approaches for high-risk smouldering myeloma M.V. Mateos Manteca
16:25 Tailoring Treatment for Elderly and Frail Patients S. Bringhen
16:50 MRD-guided therapeutic strategies M. D’Agostino
17:15 Management of Monoclonal Gammopathy of Clinical Significance A. Cagnetta

17:40 Closing R.M. Lemoli, M. Cea

Tuesday, November 4, 2025

MANAGEMENT OF HIGH-RISK PATIENTS AND RELAPSE

Chairpersons: F. Gay, E. Zamagni

09:00 How I treat high risk patients E. Zamagni
09:25 Novel strategies for induction therapy in transplant-elegible patients F. Gay
09:50 Novel strategies for relapsing patients P. Tacchetti

10:15 Coffee Break

PUSHING FORWARD EXPERIMENTAL, PRECLINICAL AND CLINICAL RESEARCH

Chairpersons: E. Angelucci, R.M Lemoli

10:30 Preclinical optimization of T cell redirected therapys M. Chesi
10:55 Single cell analysis discloses the spatial architecture of myeloma and its microenviroment L. Rasche
11:20 Bispecific Monoclonal Antibodies: Harnessing immunity to treat multiple myeloma M. Cavo
11:45 Shaping the future of immunotherapy for multiple myeloma: trispecific monoclonal antibodies C. Korst
12:10 Keynote Lecture – Future Directions in Myeloma Research: Integration and Innovation B. Bruno – Introducing M. Cea

CLOSING SESSION

12:40 Closing remarks R.M. Lemoli, M. Cea

12:50 CME Test | Closing of the Meeting

IMPORTANT NOTE: The official language of the congress will be English Translation is not foreseen

The official language of the congress will be English

Translation is not foreseen

N° 8,4 CME Italian Credits (only for italian participants) for:

Biologists
Medical Doctors (all disciplnes)

Credits available only for Italian participants

To earn CME credits is mandatory:

•Participate in at least 90% of the learning activities

•Give correct answers to at least 75% of the questions on the
« test » that will be available only at the end of the meeting (2nd day).

•Fill out the «perceived-quality & survey form»

•Sign the « sign-in sheet » at the start and end of the congress, each day

Participation in the congress is free. However, given the limited number of places, pre-registration is mandatory by filling out the online form: www.eventuallyevents.it

Registrations will be accepted based on the chronological order of arrival, until all places are filled. Access will be controlled, limited and guaranteed exclusively to registered participants and in possession of the confirmation email sent by the organizational secretariat.

Registrations will not be accepted on site and no exceptions to this effect will be permitted

Participation is free but online registration is required.

No onsite registrations will be accepted.

Registration deadline: Friday 24 October, 2025 at 11.00 AM

For online registration click below:

REGISTRATION FORM ONLINE